Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY) reported that over 60 abstracts showcasing nine of its accepted or investigational medications will be showcased during the American Society of Hematology meeting planned from December 3-6. The abstracts cover over 20 oral presentations across a diverse range of medicines and combinations. The data breadth that the company is presenting at ASH this year showcases commitment to patients with blood diseases.
Sandra Horning, MD, CMO and head of Global Product Development, said that they are thrilled to share the data of the pivotal GALLIUM trial in previously untreated follicular lymphoma. That data highlighted that subjects on Gazyva/Gazyvaro plus chemotherapy survived considerably longer without disease deteriorating compared to subjects treated with MabThera/ Rituxan plus chemotherapy.
The data from the phase 3 GALLIUM trial have been chosen for presentation in the Plenary Scientific Session, which honors the best six abstracts given to the meeting, as decided by the ASH Program Committee. Data from other trials of Gazyva®/Gazyvaro will be showcased at the meeting, including survival update from the stage 3 GADOLIN trial in MabThera®/ Rituxan® – refractory indolent non-Hodgkin lymphoma and the first report from the Phase 3 GOYA trial in previously uncured diffuse large B-celllymphoma (DLBCL).
Updated report from the Phase 3 SABRINA trial assessing subcutaneous and intravenous MabThera/ Rituxan in previously uncured follicular lymphoma will be showcased. The U.S. FDA has approved Roche Holding’s Biologics License Application for the subcutaneous preparation of Rituxan. Early data will be released for combinations of Venclyxto™/ Venclexta™ with either Gazyvaro /Gazyva or MabThera/ Rituxan in chronic lymphocytic leukaemia and different types of non-Hodgkin lymphoma.
Additional follow-up from early trials in acute myeloid leukaemia and multiple myeloma that support further assessment of Venclyxto/ Venclexta in these diseases will be presented. Venclyxto/ Venclexta is being co-developed by Roche and AbbVie. The first unit from a non-interventional trial of patients with haemophilia will be showcased, including real world efficacy and safety data from enrollments with inhibitors to factor 8 replacement therapy cured with available treatment in routine clinical practice.
Additionally, there are three pivotal trials underway to explore the efficacy and safety of emicizumab in the cure of haemophilia A.